Emergent Biosolutions (EBS) Tops Q2 EPS by 6c, Posts FY11 Guidance
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $4.49 -1.32%
Financial Fact:
Total revenues: 142.91M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Total revenues: 142.91M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Emergent Biosolutions (NYSE: EBS) reported Q2 EPS of $0.40, $0.06 better than the analyst estimate of $0.34. Revenue for the quarter came in at $88.1 million versus the consensus estimate of $84.2 million.
Emergent Biosolutions sees FY2011 net income of $15 to $25 million. Emergent Biosolutions sees FY2011 revenue of $270-$290 million, versus the consensus of $326.68 million.
Emergent Biosolutions sees FY2011 net income of $15 to $25 million. Emergent Biosolutions sees FY2011 revenue of $270-$290 million, versus the consensus of $326.68 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Emergent BioSolutions (EBS) PT Lowered to $10 at H.C. Wainwright
- MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
- Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
